Literature DB >> 2547903

Muscarinic and quisqualate receptor-induced phosphoinositide hydrolysis in primary cultures of striatal and hippocampal neurons. Evidence for differential mechanisms of activation.

A Ambrosini1, J Meldolesi.   

Abstract

Several neurotransmitters activate polyphosphoinositide (PPI) hydrolysis in CNS neurons as the first step of a transmembrane signalling cascade that may lead to neuronal circuit modulation. Muscarinic and quisqualate receptor-triggered PPI hydrolysis was investigated in neuronal primary cultures. A clear increase in inositol phosphates (Ins-Ps) was detected as early as 15 s after the agonist addition; at this time, the increases of inositol 1,4,5-trisphosphate (measured by HPLC) were relatively larger with respect to the other Ins-Ps. Ins-P accumulation was maintained in part in a Ca2+-free medium, excluding that Ca2+ entry is the fundamental step of the receptor-induced PPI hydrolysis. Acute cell pretreatment with phorbol dibutyrate, an activator of protein kinase C, was able to inhibit 50% of the response to carbachol, and almost completely the quisqualate effect, suggesting a negative feedback modulation by the enzyme. Finally, pertussis toxin failed to inhibit muscarinic responses, whereas it blocked greater than 70% of the quisqualate stimulation. The two receptors therefore appear coupled to phosphodiesterase by two different G proteins. The comparison of the results obtained by stimulating the two receptor systems suggests that the generation of the same intracellular signal at two distinct receptor types may occur by different coupling mechanisms, and be differently regulated even in the same neuronal preparations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547903     DOI: 10.1111/j.1471-4159.1989.tb11779.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  The putative molecular mechanism(s) responsible for the enhanced inositol phosphate synthesis by excitatory amino acids: an overview.

Authors:  M Récasens; J Guiramand; M Vignes
Journal:  Neurochem Res       Date:  1991-06       Impact factor: 3.996

2.  Role of calcium in regulation of phosphoinositide signaling pathway.

Authors:  J Patel; R A Keith; A I Salama; W C Moore
Journal:  J Mol Neurosci       Date:  1991       Impact factor: 3.444

3.  Pharmacological characterization of desensitization in a human mGlu1 alpha-expressing non-neuronal cell line co-transfected with a glutamate transporter.

Authors:  M A Desai; J P Burnett; N G Mayne; D D Schoepp
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 4.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

5.  Carnitine inhibits hydrolysis of inositol phospholipids induced by activation of metabotropic receptors.

Authors:  M Llansola; V Felipo
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

6.  Excitatory amino acid receptor-stimulated phosphoinositide turnover in primary cerebrocortical cultures.

Authors:  G J Birrell; F W Marcoux
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

7.  Activation of the metabotropic glutamate receptor attenuates N-methyl-D-aspartate neurotoxicity in cortical cultures.

Authors:  J Y Koh; E Palmer; C W Cotman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

8.  Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence.

Authors:  M E Fundytus; T J Coderre
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

9.  The inositol 1,4,5,-trisphosphate receptor in cerebellar Purkinje cells: quantitative immunogold labeling reveals concentration in an ER subcompartment.

Authors:  T Satoh; C A Ross; A Villa; S Supattapone; T Pozzan; S H Snyder; J Meldolesi
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.